Sign In

Laura Shapland

CEO at CareSet

Laura Shapland is a highly accomplished professional with a strong educational background and extensive experience in the healthcare industry. She holds a Mini MBA in BioPharma from Rutgers Business School, an MBA with High Honors from The University of Chicago - Booth School of Business, and a Bachelor's Degree in Psychology, Spanish, and Managerial Studies from Rice University. Laura currently serves as the CEO of CareSet, where she brings her leadership skills and expertise to drive the company forward. Previously, she was a member of the Women Business Leaders of the US Health Care Industry Foundation (WBL), showcasing her commitment to empowering and advancing women in business.

Highlights

Aug 29 · linkedin

Centers for Medicare & Medicaid Services released its Part D drug price negotiation list today (full list below).

KFF research shows that 1 in 4 Americans can't afford their meds. Achieving lower drug prices is so important for #patients.

Still, it takes a lot to make sure the #inflationreductionact has the intended impacts, especially in complex industries like #pharma and #healthcare. Really impressed with how Chiquita Brooks-LaSure and her team at CMS are tackling this so far, and will be watching closely to see how things progress...

  1. Eliquis (Bristol Myers Squibb)
  2. Jardiance (Boehringer Ingelheim)
  3. Xarelto (Janssen Inc.)
  4. Januvia (Merck)
  5. Farxiga (AstraZeneca)
  6. Entresto (Novartis)
  7. Enbrel (Amgen)
  8. Imbruvica (AbbVie)
  9. Stelara (Janssen Inc.)
  10. Fiasp and NovoLog (Novo Nordisk)
Laura Shapland
Add to my network

Location

Houston, Texas, United States